Alyeska Investment Group’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Alyeska Investment Group’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-225,000	Closed	-$297K	–	652
2023 Q1	$297K	Hold	225,000	–	–	﹤0.01%	428
2022 Q4	$380K	Hold	225,000	–	–	﹤0.01%	381
2022 Q3	$416K	Hold	225,000	–	–	﹤0.01%	364
2022 Q2	$691K	Hold	225,000	–	–	0.01%	515
2022 Q1	$1.63M	Hold	225,000	–	–	0.02%	453
2021 Q4	$3.68M	Sell	225,000 -225,000	-50%	-$2.62M	0.04%	333
2021 Q3	$4.48M	Hold	450,000	–	–	0.06%	354
2021 Q2	$4.49M	Hold	450,000	–	–	0.05%	371
2021 Q1	$4.48M	Buy	+450,000	New	+$4.65M	0.06%	346

Other funds holding PRDS

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

Alyeska Investment Group's PRDS Position: Q2 2023 in Review

Alyeska Investment Group sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q2 2023, closing a stake of 225,000 shares — an estimated $297K sold.

Alyeska Investment Group first reported a position in PRDS in Q1 2021 and held it in 9 quarters. The position peaked at $4.49M in Q2 2021. 59 funds tracked by Wall St. Rank hold PRDS as of Q2 2023.

Alyeska Investment Group reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Alyeska Investment Group sold 225,000 Pardes Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $297K.
Alyeska Investment Group first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Alyeska Investment Group's Pardes Biosciences, Inc. Common Stock position peaked at $4.49M in Q2 2021.
59 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q2 2023.

Based on Alyeska Investment Group's 13F filing for Q2 2023, filed 14 Aug 2023.